Hi, I'm C. NBC producer Katie Kramer, one of the voices behind the

the CNBC Podcast Squackpot. In these times of uncertainty, we want to make sure

we're bringing you, our listeners, as much information as possible,

as quickly as we can.

That's why we're sharing with you now

a CNBC Special Report, markets in turmoil.

Listen in.

Good evening, I'm Scott Wopner on day 109 of the coronavirus crisis.

We have major developments tonight on multiple fronts.

First, futures are surging right now on word that a drug to treat the virus is getting good

news in early data. Second, Boeing saying it will resume commercial airline production

in Washington State next week and finally new details

this evening on how the president wants to reopen the economy. We start

though with the news in the war against the coronavirus. Stat news reporting this evening that Gilead's Remdesivere

trial is seeing what they call rapid recoveries. Joining us now, the man who broke that story,

Adam Foyerstein, he is the senior writer for

stat news Adam it's good to have you on thank you for being here tell us what

you reporting found it's got thanks for having me on the show yeah so what we're

reporting tonight is that it's basically an early snapshot

of a phase three clinical trial of the drug Remdessevere, as you said,

that's being developed by Gilead scientists.

And what we were able to obtain is a report from a hospital in Chicago, which has treated about 125 people with this drug in the clinical trial and what they're saying and what

...